Apixa CCP Drug Interactions

Concomitant use of apixaban and diltiazem (a moderate CYP3A4 and weak P-gp inhibitor) increased AUC and peak plasma concentrations of apixaban by 1.4- and 1.3-fold, respectively.
Concomitant use of apixaban and ketoconazole (a strong inhibitor of both P-gp and CYP3A4) substantially increased the AUC and peak plasma concentration of apixaban by 2- and 1.6-fold, respectively.
Concomitant use of apixaban and naproxen (a P-gp inhibitor) increased the AUC and peak plasma concentration of apixaban by 1.5- and 1.6-fold, respectively.
Concomitant use of apixaban and rifampin (a strong inducer of both P-gp and CYP3A4) decreased AUC and peak plasma concentration of apixaban by 54 and 42%, respectively.
Concomitant use of apixaban and drugs that affect hemostasis (e.g., aspirin or other antiplatelet drugs, heparin or other anticoagulants, fibrinolytics, selective serotonin-reuptake inhibitors, selective serotonin- and norepinephrine-reuptake inhibitors, nonsteroidal anti-inflammatory agents (NSAIAs)) increases the risk of bleeding.